Literature DB >> 25150442

Treatment of symptomatic aberrant subclavian arteries.

H Jalaie1, J Grommes2, A Sailer3, A Greiner2, M Binnebösel4, J Kalder2, G W Schurink5, M J Jacobs6.   

Abstract

OBJECTIVE: The aim of this study is to present experience with 10 patients with symptomatic aberrant subclavian artery (ASA) and aneurysm of ASA who underwent surgical treatment.
METHODS: From 2008 to 2011 10 patients with symptomatic aberrant subclavian artery (mean age 60 years [range 24-90 years]) were studied. Symptoms were dysphagia (n = 7), dyspnea (n = 4), acute chest pain (n = 1), respiratory distress syndrome (n = 1), superior cava syndrome, and shock (n = 1). Six patients had aneurysm formation of the ASA (mean diameter of 7.1 cm [range 3.0-12.4 cm]; rupture [n = 1], dissection [n = 1]). All data were analyzed retrospectively.
RESULTS: Treatment was performed as a hybrid procedure in eight patients. This included thoracic endoluminal graft exclusion with revascularization of the ASA, a pure endovascular procedure with two occluders in one patient, and an open procedure in one patient with ligation of the aberrant artery through a thoracotomy. Three patients died during the early postoperative period owing to pulmonary complications. All three suffered from a symptomatic aneurysm, and two were treated as an emergency procedure. Median follow-up was 20 months (range 12-49 months).
CONCLUSION: A symptomatic ASA and its associated aneurysmal formation should be excluded after diagnosis. In most cases, a hybrid procedure consisting of thoracic endografting and revascularization of the ASA is feasible.
Copyright © 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aberrant subclavian artery; Dysphagia lusoria; Hybrid procedure

Mesh:

Year:  2014        PMID: 25150442     DOI: 10.1016/j.ejvs.2014.06.040

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

1.  The zonal pattern of arterial supply to the brachial plexus and its clinical significance.

Authors:  An-Bo Gao; Yun-Cheng Lv; Ai-Ping Wang; Li-Yuan Zhong; Mao-Lin Tang; Binu-Prathap Thomas; Tian-Hong Peng
Journal:  Surg Radiol Anat       Date:  2018-05-08       Impact factor: 1.246

2.  Thoracic Endovascular Aortic Repair With Subclavian Revascularization for Symptomatic Nonaneurysmal Aberrant Right Subclavian Artery.

Authors:  Yuki Nakamura; Shusuke Imaoka; Takuya Yamakura; Taro Yamasumi; Haruhiko Kondoh
Journal:  Tex Heart Inst J       Date:  2022-07-01

3.  A freaky artery.

Authors:  R Joustra; A P J van Dijk; H W J Meijburg; M Boulaksil
Journal:  Neth Heart J       Date:  2018-11       Impact factor: 2.380

4.  Asymptomatic Giant Aneurysm of the Arteria Lusoria Treated by Debranching and Aneurysmal Resection.

Authors:  Aadithiyavikram Venkatesan; Akhilesh Gonuguntla; Anila Vasireddy; Guruprasad D Rai; Ganesh Sevagur Kamath; Arvind Kumar Bishnoi; Revanth Maramreddy
Journal:  Vasc Specialist Int       Date:  2022-03-21

5.  Outcomes in the treatment of aberrant subclavian arteries using the hybrid approach.

Authors:  Sabrina Ben Ahmed; Nicla Settembre; Joseph Touma; Anthony Brouat; Jean-Pierre Favre; Elixene Jean Baptiste; Xavier Chaufour; Eugenio Rosset
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-10-10

6.  Clinical discussion of the arteria lusoria: a case report.

Authors:  Tulio Fabiano de Oliveira Leite; Lucas Alves Sarmento Pires; Rafael Cisne; Marcio Antonio Babinski; Carlos Alberto Araujo Chagas
Journal:  J Vasc Bras       Date:  2017 Oct-Dec

7.  Thrombosis of an Arteria Lusoria with Secondary Subclavian Steal Syndrome and Swallowing Difficulties.

Authors:  P Vlummens; B Houthoofd; W Janssens
Journal:  J Belg Soc Radiol       Date:  2015-12-30       Impact factor: 1.894

8.  Hybrid Treatment of Complex Aortic Arch Anomaly with Saccular Aneurysm.

Authors:  Mustafa Akbulut; Adnan Ak; Kenan Ozturker; Mesut Sismanoglu; Mehmet Altuğ Tunçer
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.